Literature DB >> 28844596

Chronic treatments with a 5-HT4 receptor agonist decrease amyloid pathology in the entorhinal cortex and learning and memory deficits in the 5xFAD mouse model of Alzheimer's disease.

Kevin Baranger1, Patrizia Giannoni2, Stéphane D Girard1, Sarah Girot1, Florence Gaven2, Delphine Stephan1, Martine Migliorati1, Michel Khrestchatisky1, Joël Bockaert2, Evelyne Marchetti-Gauthier1, Santiago Rivera1, Sylvie Claeysen3, François S Roman4.   

Abstract

Alzheimer's disease (AD) is the main cause of dementia and a major health issue worldwide. The complexity of the pathology continues to challenge its comprehension and the implementation of effective treatments. In the last decade, a number of possible targets of intervention have been pointed out, among which the stimulation of 5-HT4 receptors (5-HT4Rs) seems very promising. 5-HT4R agonists exert pro-cognitive effects, inhibit amyloid-β peptide (Aβ) production and therefore directly and positively impact AD progression. In the present work, we investigated the effects of RS 67333, a partial 5-HT4R agonist, after chronic administration in the 5xFAD mouse model of AD. 5xFAD male mice and their wild type (WT) male littermates received either RS 67333 or vehicle solution i.p., twice a week, for 2 or 4 months. Cognitive performance was evaluated in a hippocampal-dependent behavioral task, the olfactory tubing maze (OTM). Mice were then sacrificed to evaluate the metabolism of the amyloid precursor protein (APP), amyloidosis and neuroinflammatory processes. No beneficial effects of RS 67333 were observed in 5xFAD mice after 2 months of treatment, while 5xFAD mice treated for 4 months showed better cognitive abilities compared to vehicle-treated 5xFAD mice. The beneficial effects of RS 67333 on learning and memory correlated with the decrease in both amyloid plaque load and neuroinflammation, more specifically in the entorhinal cortex. The most significant improvements in learning and memory and reduction of pathology stigmata were observed after the 4-month administration of RS 67333, demonstrating that treatment duration is important to alleviate amyloidosis and glial reactivity, particularly in the entorhinal cortex. These results confirm the 5-HT4R as a promising target for AD pathogenesis and highlight the need for further investigations to characterize fully the underlying mechanisms of action.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  5-HT(4) receptor agonist; Alzheimer's disease; Memory impairments; Olfactory tubing maze; Pharmacotherapy; Transgenic mouse model

Mesh:

Substances:

Year:  2017        PMID: 28844596     DOI: 10.1016/j.neuropharm.2017.08.031

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  12 in total

Review 1.  Metalloproteinases and their tissue inhibitors in Alzheimer's disease and other neurodegenerative disorders.

Authors:  Santiago Rivera; Laura García-González; Michel Khrestchatisky; Kévin Baranger
Journal:  Cell Mol Life Sci       Date:  2019-06-13       Impact factor: 9.261

Review 2.  Understanding How Physical Exercise Improves Alzheimer's Disease: Cholinergic and Monoaminergic Systems.

Authors:  Boyi Zong; Fengzhi Yu; Xiaoyou Zhang; Wenrui Zhao; Peng Sun; Shichang Li; Lin Li
Journal:  Front Aging Neurosci       Date:  2022-05-18       Impact factor: 5.702

3.  Donecopride, a Swiss army knife with potential against Alzheimer's disease.

Authors:  Christophe Rochais; Cédric Lecoutey; Katia Hamidouche; Patrizia Giannoni; Florence Gaven; Eleazere Cem; Serge Mignani; Kevin Baranger; Thomas Freret; Joël Bockaert; Santiago Rivera; Michel Boulouard; Patrick Dallemagne; Sylvie Claeysen
Journal:  Br J Pharmacol       Date:  2020-02-11       Impact factor: 8.739

Review 4.  Opportunities for multiscale computational modelling of serotonergic drug effects in Alzheimer's disease.

Authors:  Alok Joshi; Da-Hui Wang; Steven Watterson; Paula L McClean; Chandan K Behera; Trevor Sharp; KongFatt Wong-Lin
Journal:  Neuropharmacology       Date:  2020-05-04       Impact factor: 5.250

Review 5.  Alterations of Expression of the Serotonin 5-HT4 Receptor in Brain Disorders.

Authors:  Heike Rebholz; Eitan Friedman; Julia Castello
Journal:  Int J Mol Sci       Date:  2018-11-13       Impact factor: 5.923

Review 6.  Hippocampal Deficits in Amyloid-β-Related Rodent Models of Alzheimer's Disease.

Authors:  Yukti Vyas; Johanna M Montgomery; Juliette E Cheyne
Journal:  Front Neurosci       Date:  2020-04-07       Impact factor: 4.677

Review 7.  Emerging Alternative Proteinases in APP Metabolism and Alzheimer's Disease Pathogenesis: A Focus on MT1-MMP and MT5-MMP.

Authors:  Laura García-González; Dominika Pilat; Kévin Baranger; Santiago Rivera
Journal:  Front Aging Neurosci       Date:  2019-09-24       Impact factor: 5.750

8.  Serotonin 5-HT4 Receptor Agonists Improve Facilitation of Contextual Fear Extinction in an MPTP-Induced Mouse Model of Parkinson's Disease.

Authors:  Toshiaki Ishii; Ken-Ichi Kinoshita; Yoshikage Muroi
Journal:  Int J Mol Sci       Date:  2019-10-26       Impact factor: 5.923

Review 9.  The gut microbiota to the brain axis in the metabolic control.

Authors:  Estelle Grasset; Remy Burcelin
Journal:  Rev Endocr Metab Disord       Date:  2019-12       Impact factor: 6.514

10.  Déjà-vu? Neural and behavioural effects of the 5-HT4 receptor agonist, prucalopride, in a hippocampal-dependent memory task.

Authors:  Angharad N de Cates; Lucy C Wright; Marieke A G Martens; Daisy Gibson; Cagdas Türkmen; Nicola Filippini; Philip J Cowen; Catherine J Harmer; Susannah E Murphy
Journal:  Transl Psychiatry       Date:  2021-10-04       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.